Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Press Announcements

Press Announcements Home
          News & Events
          FDA Newsroom
          Press Announcements
          Coronavirus (COVID-19) Update: FDA to Hold Advisory Committee Meeting to Discuss Future Vaccination Regimens Addressing COVID-19Press Announcements FDA Statement
  Coronavirus (COVID-19) Update: FDA to Hold Advisory Committee Meeting to Discuss Future Vaccination Regimens Addressing COVID-19

  
  Share
    Post
    Linkedin

    Email
    PrintFor Immediate Release:
                  December 16, 2022
                 
                         Statement From:
         Peter  Marks, M.D., PhD.            Director - Center for Biologics Evaluation and Research (CBER)
 

  
      
       

  On Jan. 26, 2023, the U.S. Food and Drug Administration will hold a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to consider whether and how the composition for primary doses of the currently available COVID-19 vaccines should be modified and how and whether the composition and schedule for booster doses should be adjusted moving forward. Along with the independent experts of the advisory committee, representatives from the U.S. Centers for Disease Control and Prevention and the National Institutes of Health will also participate in the meeting.

COVID-19 vaccines remain our best available protection against COVID-19, particularly the most devastating consequences of the disease, including hospitalization and death. Since the initial authorizations of these vaccines, we have learned that protection wanes over time, especially as the virus rapidly mutates and new variants and subvariants emerge. Therefore, it’s important to continue discussions about the optimal composition of COVID-19 vaccines for primary and booster vaccination, as well as the optimal interval for booster vaccination.

At the upcoming January meeting, the agency is planning to examine the state of the pandemic, the evolution of variants and subvariants, and the available effectiveness, safety and immunogenicity data with the current monovalent and bivalent vaccines. The agency will also consider the potential composition of the current and next generation of COVID-19 vaccines for primary and booster immunization. There will also be presentations from manufacturers and the FDA summarizing the manufacturing considerations and timelines related to vaccine composition changes. Following the discussion and taking into account the advice provided by the VRBPAC at the meeting, the FDA will consider whether to recommend adjustments to the current authorizations and approvals, and the FDA will consider the most efficient and transparent process to use for selection of strains for inclusion in the primary and booster vaccines.

We are hopeful this upcoming discussion will provide us with the optimal path forward for COVID-19 vaccines, helping to ensure that the public remains best protected from evolving virus variants.

In June 2022, the FDA held a VRBPAC meeting to discuss whether a change in the vaccine strain composition of COVID-19 vaccines for booster doses was necessary for the 2022 fall and winter seasons given that the virus had mutated significantly, and the omicron variants were most prevalent. After an overwhelming majority of the committee voted in favor of including a SARS-CoV-2 omicron component in COVID-19 boosters, the FDA advised manufacturers that, based on the best available data, they should develop modified COVID-19 vaccines that included an omicron BA.4/5 spike protein component to the vaccine composition to create a two component (bivalent) booster vaccine. The agency did not advise manufacturers to change the compositions of vaccines used for primary vaccination because at the time the available clinical data did not support making such a recommendation.

We intend to make background material available to the public, including the meeting agenda and committee roster, no later than two business days before the meeting. The meeting also will be livestreamed on the agency’s YouTube channel and webcast from the FDA website.

  Related Information
  
  Related Information
              Vaccines and Related Biological Products Advisory Committee
	COVID-19 Vaccines
	Emergency Use Authorization for Vaccines Explained

###
  Boilerplate
      The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Inquiries
  
    
        
         Media:
                 
      
                            Abby Capobianco
           
           
                      240-461-9059
    Consumer:
                        888-INFO-FDA

                                                                                  Content current as of:
      12/16/2022
               
               
Regulated Product(s)
		 BiologicsHealth Topic(s)
			  Infectious Disease
			    			       			    			       Coronavirus   

        Follow FDA
            Follow @US_FDAon X
                Follow FDAon Facebook
                Follow @FDAMediaon XMore Press Announcements
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop